NCT05162066 - Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

September 23, 2022

Study Completion Date

September 23, 2022

Conditions

Complement 3 GlomerulopathyImmunoglobulin A NephropathyMembranous Nephropathy

Interventions

DRUG

BCX9930

Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Trial Locations (11)

Investigative Site, Poitiers

Investigative Site, Toulouse

Investigative Site, Bari

Investigative Site, Bergamo

Investigative Site, Brescia

Investigative Site, Turin

Investigative Site #1, Barcelona

Investigative Site #2, Barcelona

Investigative Site #1, Madrid

Investigative Site #2, Madrid

Investigative Site, Oxford